Showing results (181-190 of 215) with videos related to
Sort By:
Pageof 22
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2025
Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 AntibodiesAlexandra Jungova, Martin Stork, Ivan Spicka, et al.Blood|January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportAntonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.Hemasphere|September 25, 2025
Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myelomaJuan-Jose Garces, Benjamin Diamond, Tereza Sevcikova, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2022
Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple MyelomaLarissa Haertle, Santiago Barrio, Umair Munawar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationLaurent Garderet, Simona Iacobelli, Philippe Moreau, et al.The Lancet. Oncology|June 3, 2023
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma NetworkHeinz Ludwig, Evangelos Terpos, Niels van de Donk, et al.Blood|October 8, 2025
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasoneLuca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2022
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple MyelomaTomas Jelinek, Renata Bezdekova, David Zihala, et al.Leukemia|August 21, 2020
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma NetworkHeinz Ludwig, Mario Boccadoro, Philippe Moreau, et al.Blood Cancer Journal|October 17, 2020
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)María-Victoria Mateos, Shaji Kumar, Meletios A Dimopoulos, et al.Pageof 22